A phase Ib/II study of fruquintinib in combination with SOX and toripalimab as first-line treatment for advanced metastatic gastric/gastroesophageal junction adenocarcinoma (GC/GEJC).

被引：0
|
作者：
Meng, Xiangrui [1 ]
Shan, Zhengzheng [1 ]
Guan, Lulu [1 ]
Dao, Xin [1 ]
Fan, Qingxia [1 ]
Wang, Feng [1 ]
机构：
[1] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 3_SUPPL期
关键词：
261-492-5651-9270-10662; 298-145-222-184-1022-9124; 261-566-9718-9794; 130-540-543-4790; 261-492-2769; 3282-3306-2666-6279; 3282-3306-4614-3827; 3; 2; 2461; 3216; 1704; 239; 6; 1; 38092-34311; 38092-21759; 38116-38094-8; 38092-20072;
D O I：
10.1200/JCO.2024.42.3_suppl.335
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：335 / 335
页数：1
相关论文
共 50 条
  • [31] A phase II study: Combination of sorafenib with docetaxel and cisplatin in the treatment of metastatic or advanced unresectable gastric and gastroesophageal junction (GEJ) adenocarcinoma (ECOG 5203)
    Sun, W.
    Powell, M. E.
    O'Dwyer, P.
    Ansari, R. H.
    Benson, A. B., III
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [32] A multicentre, open-label phase II study of irinotecan, capecitabine, and oxaliplatin (IXO) as first-line treatment in patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
    Lui, Arthur Gregory Ang
    Mulder, Karen E.
    Brezden-Masley, Christine
    Vickers, Michael M.
    Monzon, Jose Gerard
    Kennecke, Hagen F.
    Goel, Rakesh
    Ghosh, Sunita
    Marginean, Horia
    Vos, Larissa Joy
    Raynard, SeeSee Juliana
    Young, Kristine Lee
    Fields, Anthony L. A.
    Maroun, Jean Alfred
    Spratlin, Jennifer L.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [33] Phase II study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results.
    Pinto, C.
    Di Fabio, F.
    Siena, S.
    Cascinu, S.
    Llimpe, F. L. Rojas
    Ceccarelli, C.
    Mutri, V.
    Giaquinta, S.
    Piana, E.
    Martoni, A. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 186S - 186S
  • [34] Toripalimab combined with nab-paclitaxel/gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma: Updated results of a phase Ib/II clinical study.
    Cheng, Ke
    Lv, Wanrui
    Li, Xiaofen
    Chang, Chen
    Cao, Dan
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16244 - E16244
  • [35] Cetuximab in combination with FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastrooesophageal junction (GEJ) adenocarcinoma: Preliminary results of the italian phase II study
    Pinto, C.
    Di Fabio, F.
    Siena, S.
    Cascinu, S.
    Rojas, Llimpe F.
    Ceccarelli, C.
    Mutri, V
    Giaquinta, S.
    Piana, E.
    Martoni, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 97 - 97
  • [36] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Bang, Yung-Jue
    Kang, Yoon-Koo
    Catenacci, Daniel V.
    Muro, Kei
    Fuchs, Charles S.
    Geva, Ravit
    Hara, Hiroki
    Golan, Talia
    Garrido, Marcelo
    Jalal, Shadia I.
    Borg, Christophe
    Doi, Toshihiko
    Yoon, Harry H.
    Savage, Mary J.
    Wang, Jiangdian
    Dalal, Rita P.
    Shah, Sukrut
    Wainberg, Zev A.
    Chung, Hyun Cheol
    GASTRIC CANCER, 2019, 22 (04) : 828 - 837
  • [37] DKN-01 in Combination With Tislelizumab and Chemotherapy as First-Line Therapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: DisTinGuish
    Klempner, Samuel J.
    Sonbol, Mohamad Bassam
    Wainberg, Zev A.
    Uronis, Hope Elizabeth
    Chiu, Vi K.
    Scott, Aaron James
    Iqbal, Syma
    Tejani, Mohamedtaki Abdulaziz
    Chung, Vincent
    Stilian, Melissa C.
    Thoma, Mathis
    Zhang, Ying
    Kagey, Michael H.
    Baum, Jason
    Sirard, Cynthia A.
    Altura, Rachel A.
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (03)
  • [38] Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
    Yung-Jue Bang
    Yoon-Koo Kang
    Daniel V. Catenacci
    Kei Muro
    Charles S. Fuchs
    Ravit Geva
    Hiroki Hara
    Talia Golan
    Marcelo Garrido
    Shadia I. Jalal
    Christophe Borg
    Toshihiko Doi
    Harry H. Yoon
    Mary J. Savage
    Jiangdian Wang
    Rita P. Dalal
    Sukrut Shah
    Zev A. Wainberg
    Hyun Cheol Chung
    Gastric Cancer, 2019, 22 : 828 - 837
  • [39] Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study
    Deleporte, Amelie
    Van den Eynde, Marc
    Forget, Frederic
    Holbrechts, Stephane
    Delaunoit, Thierry
    Houbiers, Ghislain
    Kalantari, Hassan R.
    Laurent, Stephanie
    Vanderstraeten, Erik
    De Man, Marc
    Vergauwe, Philippe
    Clausse, Marylene
    Van der Auwera, Jacques
    D'Hondt, Lionel
    Pierre, Pascal
    Ghillemijn, Bjorn
    Covas, Angelique
    Paesmans, Marianne
    Ameye, Lieveke
    Awada, Ahmad
    Sclafani, Francesco
    Hendlisz, Alain
    CANCER MEDICINE, 2021, 10 (13): : 4366 - 4374
  • [40] A phase II trial of first-line FOLFIRINOX for patients with advanced gastroesophageal adenocarcinoma
    Park, Haeseong
    Wang-Gillam, Andrea
    Suresh, Rama
    Rigden, Caron E.
    Amin, Manik A.
    Tan, Benjamin R.
    Pedersen, Katrina
    Lim, Kian-Huat
    Trikalinos, Nikolaos
    Navo, Katherine
    Morton, Ashley
    Schrumpf, Lindsey
    Marquez, Samantha
    Trinkaus, Kathryn
    Lockhart, A. Craig
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
12345